Skip to main content
| News

Forty51 closes first fund totaling 43 million US dollars

19.07.2022

A new Basel-based venture fund, Forty51 Ventures I, has raised a total of 43 million US dollars following a first fund closing. Forty51 invests in European biotech firms with clear clinical pathways. The first investment took the form of early stage financing for Mosanna Therapeutics from Basel.

lab

Forty51 Ventures has announced the first closing of its Biotech Venture Capital Fund I and its first investment. In a press release, the company provides details in connection with a deal worth 43 million US dollars. The core strategy of the company, which was founded in Basel in April 2022, aims to support the founding of start-ups and early stage investments in the biotechnology sector, primarily in Switzerland, France and Germany.

The fund, which is based in Luxembourg, is being advised by a three-strong founding team who boast an extensive network and decades of experience in the area of drug development, transactions and venture capital. In addition, the team works with prominent figures within the industry and a strategic partner in the USA.

Investment in biotech

In addition to the closing, Forty51 has also announced its first investment. Mosanna Therapeutics, a biotech firm also recently founded in Basel, is the beneficiary of this. Forty51 led this early stage financing round. The consortium of investors also includes the London-based firm Stable Asset Management and the Fischli family. Mosanna is working on a small molecule developed by Sanofi to treat patients with metabolic obstructive sleep apnea.

“Forty51 Ventures brings true company building to Europe’s exciting Biotech scene”, comments Erik Serrano-Berntsen, CEO and founder of Stable Asset Management, in the press release. “I have not come across a truly differentiating investment strategy in biotech coupled with such a highly complementary skillset among the founding partners”, he concludes.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area achieves milestone with settling of LifeMine
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Basel Area achieves milestone with settling of LifeMine

Life sciences company LifeMine Therapeutics from the USA has established its European headquarters in the Basel Area. With this, Basel...

Read More
Space Pharmaceuticals establishes presence in Basel
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Space Pharmaceuticals establishes presence in Basel

Space Pharmaceuticals AG is strengthening the life sciences cluster in the Basel Area. At its research lab, the cheminformatics company...

Read More
Basel Area Business & Innovation, Innovation, Life Sciences / biotech

NextImmune to benefit from Venture Kick financing

The startup accelerator Venture Kick is supporting NextImmune with financing in the amount of 150,000 Swiss francs. The spin-off from...

Read More
Basel Area Business & Innovation, Innovation, Medtech, Switzerland Innovation Park

OECD impressed by the canton of Jura’s innovation system

The OECD has examined the innovation systems in place in rural areas of its member states, including the canton of...

Read More
Basel Area Business & Innovation, ICT, Innovation, Invest

ti&m opens branch in Basel

ti&m now has an office in Basel. With this action, the company specializing in digitization, security and innovation projects is...

Read More
What can artificial intelligence do for health?
Basel Area Business & Innovation, Digital Health, Innovation, Life Sciences / biotech, Medtech

What can artificial intelligence do for health?

Algorithms help diagnose and treat diseases, discover new drugs and personalize prevention. Thus, the potential of artificial intelligence has been...

Read More
1 2 3 56

Do you have a question? We'd like to hear from you.